Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen, a developer of human therapeutics, has received a US patent 8,063,182 for its Enbrel (etanercept).
Subscribe to our email newsletter
The entitled patent owned by Hoffman-La Roche’s (Roche) was licensed to Amgen upon a one-time payment and received an exclusive, fully paid-up license to the application which issued today as the ‘182 patent.
Enbrel is a soluble form of a fully human tumor necrosis factor (TNF) receptor.
In 1998, Enbrel was approved in the US to treat moderate to severe rheumatoid arthritis and later in 1999 was approved to treat children and adolescents with moderate to severe juvenile rheumatoid arthritis (juvenile idiopathic arthritis).
In the US, Enbrel was approved to treat adult chronic moderate to severe plaque psoriasis in 2004.